Company / Return on Assets (ROA)
Viridian Therapeutics, Inc.\DE Return on Assets (ROA) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-38.1%
FY2025
5-year range
-48.5% / -29.8%
FY2021-FY2025
Trend
-4.8%
vs FY2024
Sector context
#154 of 213
Health Care
What the data says
At -38.1%, Viridian Therapeutics, Inc.\DE's return on assets (roa) ranks #154 of 213 in the Health Care sector. Return on Assets (ROA) has fluctuated over the past 10 years, ranging from -138.4% in FY2019 to -29.8% in FY2022.
Based on SEC 10-K filings.
-38.1% in FY2025 with a 5-year CAGR of +46.3%.
Improved from -48.5% to -38.1% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -8.2pp
- 5-Year Change
- +46.3pp
- 10-Year Change
- -
Sector benchmark
#154 of 213 in Health CareTop 72% of 213This company -38.1% Sector average -24.1%
▼
-57.8% below sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) decreased 4.8% year-over-year.
- Currently 14.0pp below the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2022.
- Lowest return on assets (roa) in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -38.1% | -4.8% |
| FY2024 | -36.4% | +25.0% |
| FY2023 | -48.5% | -62.4% |
| FY2022 | -29.8% | +23.4% |
| FY2021 | -39.0% | +53.8% |
| FY2020 | -84.4% | +39.0% |
| FY2019 | -138.4% | -179.9% |
| FY2018 | -49.4% | +2.1% |
| FY2017 | -50.5% | +27.6% |
| FY2016 | -69.8% | +20.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026